Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 4NIH 2INDUSTRY 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Carcinoma, Islet Cell 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Streptozocin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00001165 2008-03-04

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
999 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Zollinger-Ellison Syndrome, Gastrinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡